Pulmonary artery wall thickness in children with Fontan physiology: an optical coherence tomography case control

Eimear McGovern1, Christine Voss1, Nathan W Brunner2

  • 1Division of Cardiology, Department of Pediatrics, British Columbia Children's Hospital, 4480 Oak Street, Vancouver, BC, V6H 3V4,Canada.

Insights

Optical coherence tomography (OCT) is safe for evaluating pulmonary arteries in Fontan circulation patients. Childhood pulmonary artery dimensions appear normal in Fontan patients with stable hemodynamics.

Area of Science:

  • Cardiovascular Research
  • Pediatric Cardiology
  • Medical Imaging

Background:

  • Fontan circulation failure is poorly understood, with potential links to pulmonary vascular resistance and structural pulmonary artery changes.
  • Investigating these structural changes is crucial for understanding Fontan circulation failure.
  • Optical coherence tomography (OCT) offers a novel approach to assess pulmonary artery structure.

Purpose of the Study:

  • To evaluate structural changes in the pulmonary arteries of Fontan patients using OCT.
  • To compare pulmonary artery structure between Fontan patients and healthy controls.
  • To assess the feasibility and safety of pulmonary artery OCT in Fontan patients.

Main Methods:

  • Pulmonary artery OCT was performed in 12 Fontan patients and 11 controls.
  • Wall thickness and wall-to-vessel cross-sectional area (CSA) ratio were calculated using digital planimetry.
  • Safety and feasibility of the OCT procedure were assessed.

Main Results:

  • No significant differences in pulmonary artery wall thickness or wall:vessel CSA ratio were found between Fontan patients and controls.
  • Pulmonary artery wall dimensions in Fontan patients showed no association with hemodynamic parameters or clinical factors.
  • The vessel media layer was less consistently visualized in Fontan patients compared to controls.

Conclusions:

  • Pulmonary artery OCT is a safe and feasible imaging modality for Fontan patients.
  • Fontan children with reassuring hemodynamics exhibit normal pulmonary artery wall dimensions during childhood.
  • Further research is needed to determine OCT's utility in identifying early structural changes in Fontan patients with abnormal hemodynamics and into adulthood.
Abstract

Related Concept Videos

Physiological Control of Respiration01:23

Physiological Control of Respiration

Introduction
Breathing, a seemingly passive process, is regulated by the respiratory center in the brainstem. This center coordinates the involuntary control of respirations, which means it occurs without conscious effort, ensuring a smooth and uninterrupted pattern.
Regulation of Ventilation
The body maintains ventilation by monitoring levels of carbon dioxide (CO2), oxygen (O2), and hydrogen ion concentration (pH) in the arterial blood. Among these factors, the level of CO2 plays a crucial...
6.0K
Physiology of Respiration II: Neurogenic Control of Respiration01:22

Physiology of Respiration II: Neurogenic Control of Respiration

The neurogenic control of respiration coordinates various neural networks and pathways to regulate breathing rate and depth, meeting the body's oxygen and carbon dioxide exchange requirements. This system adapts to physiological and environmental conditions, ensuring optimal breathing patterns.
Central Control
The brainstem is the primary site of central control, hosting respiratory centers:
1.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
587
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
419
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
452
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
480